Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Biologics CDMO Secondary Packaging Global Market Report 2022: Sector to Generate $3.62 Billion by 2030

DUBLIN, Jan. 28, 2023 /PRNewswire/ -- The "Biologics CDMO Secondary Packaging Market Size and Share Analysis by Type, Primary Package Type - Global Industry Revenue Estimation and Demand Forecast to 2030" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The biologics CDMO secondary packaging market has captured $1,711.7 million revenue in 2021, and it is projected to rise at a rate of 8.7% in the coming years, to generate $3,622.6 million revenue in 2030, according to P&S Intelligence. It is due to the rising pharmaceutical production and increasing incidence of infectious diseases, genetic disorders, and chronic diseases.

Expansion of Businesses Propels Industry

The surging expenditure by several companies to expand their businesses in various geographies propels the industry. For instance, Catalent Inc. invested $350 million in April 2022 to expand drug manufacturing in Bloomington, Indiana.

Over the years, biological product production has risen, which has driven the demand for materials for secondary packing. In the U.S., the pharmaceutical industry offers a wide array of new drugs to enhance patient outcomes.

Rising Biopharmaceutical Application Boosts Industry Growth

Moreover, the surging pace of improvements in biopharmaceutical manufacturing, for the creation of biologics that can enhance medical care, are driving the market. Small and medium-sized companies are focusing on collaborations with CDMOs to improve the success of their products and survive in an industry that is dynamic and continuously transforming.

Currently, there are more than 7,800 products in the development stage for various therapeutic areas, such as cardiovascular, cancer, neurology, and diabetes, on account of the major investments in research and development.

For instance, WuXi Biologics began a collaboration with BravoBio Co. Ltd. in January 2022 to boost the production of vaccines for infectious diseases. BravoBio utilizes the integrated platforms of WuXi Vaccines for conducting preclinical research, manufacturing clinical supplies in compliance with GMP, and ensuring the worldwide supply of vaccines.

High Success Potential of Clinical-Phase Products

Furthermore, around 70% of the clinical-phase projects have shown the potential to perform better than the current drugs for specific indications. The undertrial pipeline includes products that may offer physicians novel approaches to disease management.

Boxes Are Preferred Secondary Packaging among Biologics CDMOs

Blister Packs Hold Largest Industry Share

Under primary package type, blister packs captured the largest industry share in 2021, of 40%. This category is also projected to witness the fastest growth in the coming years. It is because the majority of the CDMOs offer secondary packaging services for this kind of primary package.

Market Dynamics




Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Definition of Market Segments
6.1 By Type
6.1.1 Boxes
6.1.2 Cartons
6.1.3 Others
6.2 By Primary Package Type
6.2.1 Ampoules
6.2.2 Blister Packs
6.2.3 Bottles
6.2.4 Cartridges
6.2.5 Syringes and Vials
6.2.6 Prefilled Syringes
6.2.7 Others

Chapter 7. Industry Outlook

Chapter 8. Global Market Size and Forecast

Chapter 9. North America Market Size and Forecast

Chapter 10. Europe Market Size and Forecast

Chapter 11. APAC Market Size and Forecast

Chapter 12. LATAM Market Size and Forecast

Chapter 13. MEA Market Size and Forecast

Chapter 14. Biologics CDMO Secondary Packaging Equipment Market

Chapter 15. Sterile Products Packaging Equipment Market

Chapter 16. Competitive Landscape

Chapter 17. Company Profiles

Chapter 18. Appendix

Companies Covered

For more information about this report visit https://www.researchandmarkets.com/r/vd134y-cdmo?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

These press releases may also interest you

at 22:56
Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achieved blistering performance, and contract development...

at 21:45
The "Global Cell Dissociation Market by Product (Trypsin, Papain, DNase, Hyaluronidase, Instruments), Tissue Type (Connective Tissue, Epithelial Tissue), End-user (Pharma, Biopharma, Research Institutes) & Region - Forecast to 2028" report has been...

at 21:00
The "Global Medical Tubing Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Material, Structure, Application, End-User, and Major Regions" report has been added to  ResearchAndMarkets.com's offering. According to this analysis, the...

at 21:00
Asia Pacific Medical Technology Association (APACMed), the region's leading organization for medical technology manufacturers, has named  EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry and a market...

at 20:45
The "Global Hospital Furniture Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Manufacturing Material, Application, End User, Region" report has been added to  ResearchAndMarkets.com's offering. According to this...

at 20:25
Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public...

News published on 28 january 2023 at 06:10 and distributed by: